Medicine
Sylvant 400 mg powder for injection
Sylvant 400 mg powder for injection is a prescription medicine containing Siltuximab for intravenous use, marketed by Recordati Rare Diseases, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
and Stability SYLVANT must be refrigerated at 2°C to 8°C (36°F to 46°F) in the…
Key facts
- Active ingredient (INN)
- Siltuximab
- Brand
- Sylvant
- Strength
- 400 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Recordati Rare Diseases
- Manufacturer
- Recordati Rare Diseases
- Origin register
- US FDA, United States
- Storage
- and Stability SYLVANT must be refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC11 Siltuximab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 April 2014
- Identifiers
- RxCUI 1658132, 1658135, 1658139 +1DailyMed set ID 8d663642-f52e-49c0-a023-2da083fdfc0bNDC 73090-421Application BLA125496
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 box / 1 injection, powder, for solution in 1 vial, single-dose | 73090-421-01 | Recordati Rare Diseases | 23 April 2014 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Siltuximab
Clinical summary
Siltuximab is an interleukin-6 antagonist indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MedsAcross supplies Siltuximab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SiltuximabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sylvant prescribing information (Recordati Rare Diseases) · U.S. National Library of Medicine, DailyMed
- Sylvant: European public assessment report (EPAR) · European Medicines Agency
Need Sylvant 400 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.